Plain-English translation of NCT05845489 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Coronary Artery Disease research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether clopidogrel, a blood-thinning medication, can help prevent heart attacks and other serious heart events in people who have early signs of coronary artery disease (narrowing of the heart's blood vessels) but haven't had a heart attack or needed surgery. Researchers want to know if the medication is both effective at preventing these events and safe to use long-term in this group of patients.
Most blood-thinning medications are only proven to work after someone has already had a heart attack, but many people have early signs of artery disease without knowing it and are at risk for future problems. This trial exists to find out whether this medication can actually prevent heart attacks in people at this earlier stage, before serious events happen.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to either take the medication once daily for at least 5 years, or to not take any blood-thinning medication during that time. You will have regular follow-up visits over the 5-year period so researchers can check how you are doing and watch for any heart events or side effects. Your doctors will monitor you closely and can add blood-thinning medication if a medical need arises during the study.
AI-generated summary from trial data · Jul 1, 2026 · Not medical advice
South Korea